Development of conditions for Pyrazidol identification in the urine in the presence of its biotransformation products by thin layer chromatography and mass spectrometry
Keywords:Pyrazidol; dehydropyrazidol; biofluids; thin layer chromatography; color reactions; mass spectrometry
For the analytical diagnosis of drug poisoning, it is important to develop conditions for the detection of both native compounds and products of their biotransformation in biological samples.
Aim. To develop a method for isolating the antidepressant drug Pyrazidol from the human urine in the presence of its biotransformation products and determine the conditions that are suitable for analytical diagnostics of thymoleptic intoxication for their detection by thin layer chromatography.
Materials and methods. The study was conducted with the human urine samples collected after taking a single therapeutic dose of Pyrazidol. The urine was subjected to the acid hydrolysis, and the antidepressant and its metabolites were extracted from the hydrolysate with chloroform from an alkaline medium at pH 8-9. Concomitant endogenous admixtures were removed by extraction with diethyl ether from an acidic medium at pH 1. For the chromatographic study of the extracts, four mobile phases recommended by the International Association of Forensic Toxicologists for TLC screening of drugs, and Merck chromatographic plates were used. Color reactions were performed on pieces of chromatographic plates with a number of chromogenic reagents most commonly used in chemico-toxicological analysis. Metabolites were identified by electron impact mass spectrometry.
Results and discussion. The native substance and dehydropyrazidol were detected in the urine hydrolysates by TLC, their chromatographic mobility parameters in four TLC screening systems, as well as the results of their color reactions with the chromogenic reagents were determined.
Conclusions. Conditions for isolating Pyrazidol and its biotransformation product from the urine have been proposed. The method for detecting the native compound and dehydropyrazidol in the urine extracts by TLC and mass spectrometry after taking a single therapeutic dose of the drug has been developed. The method is recommended for use in the practice of forensic and clinical toxicology.
The effects of chronic stress on hippocampal adult neur ogenesis and dendritic plasticity are reversed by selective MAO-A inhibition / M. Morais et al. Journal of Psychopharmacology. 2014. Vol. 28, Iss. 12. P. 1178–83. DOI: https://doi.org/10.1177/0269881114553646.
Pirlindole in the Treatment of Depression and Fibromyalgia Syndrome / J. C. Branco et al. Clinical Drug Investigation. 2011. Vol. 31, Iss. 10. P. 675–689. DOI: https://doi.org/10.2165/11595410-000000000-00000.
Macedo A., Leiria E., Filipe A. Pirlindole in the Treatment of Depression : a meta-analysis. Clinical Drug Investigation. 2011. Vol. 31, Iss. 1. P. 61–71. DOI: https://doi.org/10.2165/11586690-000000000-00000.
Entzeroth M., Ratty A. K. Monoamine Oxidase Inhibitors – Revisiting a Therapeutic Principle. Open Journal of Depression. 2017. Vol. 6, Iss. 2. P. 31–68. DOI: https://doi.org/10.4236/ojd.2017.62004.
Patil A. J., Suryawanshi M. R. Review on Novel Monoamine Oxidase Inhibitors: A Clinician’s Guide. Open Access Journal of Pharmaceutical Research. 2021. Vol. 5, Iss. 2. P. 000240. URL: https://medwinpublishers.com/OAJPR/review-on-novel-monoamine-oxidaseinhibitors-a-clinician-s-guide.pdf. DOI: https://doi.org/10.23880/oajpr-16000240.
Monoamine oxidase inhibitors (MAOIs) for fibromyalgia syndrome / S. Tort et al. Cochrane Database of Systematic Reviews. 2012. № 4. P. CD009807. DOI: https://doi.org/10.1002/14651858.CD009807.
Pirlindole. DrugBank Online. URL: https://go.drugbank.com/drugs/DB09244.
Машковский М. Д. Лекарственные средства. 16-е изд., перераб., испр. и доп. Москва : Новая Волна, 2020. 1216 с.
Automated determination of pirlindole enantiomers in plasma by on-line coupling of a pre-column packed with restricted access material to a chiral liquid chromatographic column / P. Chiap et al. Journal of Pharmaceutical and Biomedical Analysis. 2002. Vol. 27, Iss. 3-4. Р. 447–455. DOI: https://doi.org/10.1016/s0731-7085(01)00647-1.
Moffat A. C., Osselton M. D., Widdop B. Clarke’s analysis of drugs and poisons in pharmaceuticals, body fluids and postmortem material. 4-th ed. London, Chicago : Pharmaceutical Press, 2011. 2736 p.
Tomarovska L. Yu., Baiurka S. V., Karpushina S. A. Development of the methods for atomoxetine identification suitable for the chemical and toxicological analysis. News of Pharmacy. 2017. № 2 (90). P. 13–20. DOI: https://doi.org/10.24959/nphj.17.2154.
Copyright (c) 2022 National University of Pharmacy
This work is licensed under a Creative Commons Attribution 4.0 International License.Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).